FDA warning letters target marketers of unapproved weight loss drugs RAPS The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide BPC 157 Weight Loss: Evidence & Safety The FDA just put peptides like BPC 157, TB 500, and KPV on the clock. , As a compounding pharmacist, this is literally my world and most people dont understand the regulatory nuance behind what BPC 157 Peptide Erectile Dysfunction: What the Evidence Shows and Practical Considerations